EVOREL CONTI Patch Ref.[50563] Active ingredients: Estradiol Norethisterone

Source: Health Products Regulatory Authority (ZA)  Revision Year: 2021  Publisher: Adcock Ingram Limited, 1 New Road, Erand Gardens, Midrand 1685, South Africa

Product name and form

EVOREL CONTI.

Patch.

Pharmaceutical Form

EVOREL CONTI is a matrix type transdermal patch.

EVOREL CONTI is a flexible, square, colourless adhesive patch of 16 cm 2 with convex edges and rounded corners. The adhesive surface of the patch is covered with a protective foil with an S shaped incision.

Each patch is marked in the centre of the lower margin on the outside of the backing film: CEN1.

Qualitative and quantitative composition

Each EVOREL CONTI patch contains 3,1 mg estradiol, formulated as 3,2 mg of estradiol hemihydrate and 9,82 mg norethisterone, formulated as 11,2 mg of norethisterone acetate. The patch delivers 50 μg of estradiol and 170 μg of norethisterone acetate per 24 hours. EVOREL CONTI contains no sugar.

For full list of excipients, see section 6.1.

Active Ingredient Description
Estradiol

Estradiol, is chemically and biologically identical to endogenous human estradiol. It substitutes for the loss of oestrogen production in menopausal women, and alleviates menopausal symptoms. Oestrogens prevent bone loss following menopause or ovariectomy.

Norethisterone

Norethisterone has progestational actions similar to those of progesterone, but is a more potent inhibitor of ovulation and has weak oestrogenic and androgenic properties. It is used to treat a number of disorders of the menstrual cycle.

List of Excipients

Adhesive: acrylate vinylacetate copolymer
Guar gum
Backing film: polyethylene terephthalate foil
Release liner: siliconised polyethylene terephthalate foil which is removed before application.

Pack sizes and marketing

Cartons containing eight EVOREL CONTI patches in foil lined pouches.

The pouch comprises a 4 layer laminate including an aluminium barrier and paper exterior surface.

Marketing authorization holder

Adcock Ingram Limited, 1 New Road, Erand Gardens, Midrand 1685, South Africa

Marketing authorization dates and numbers

31/21.8.2/0537

Namibian Reg No.: 04/21.8.2/0244
NS 2

Date of registration: 16 February 1998

Drugs

Drug Countries
EVOREL CONTI Finland, Ireland, Israel, Mexico, United Kingdom, South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.